An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Infinity to Participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Infinity Pharmaceuticals (NASDAQ: INFI) has announced its participation in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit as well as the 3rd Annual Macrophage-directed Therapies Summit. The Oppenheimer event will include a live presentation on September 20 at 1:15 PM ET, along with 1-on-1 meetings from September 20 to 22. The Macrophage-directed Therapies Summit will take place on September 30 at 4:00 PM ET, focusing on the synergistic potential of eganelisib with frontline treatments. Further details are available on Infinity's website.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and at the 3rd Annual Macrophage-directed Therapies Summit.
Presentation details can be found below:
Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Format: Live presentation and 1-on-1 meetings
Date and Time: September 20th at 1:15pm ET; 1-on-1 meetings September 20 - 22 Webcast Link: https://wsw.com/webcast/oppenheimer16/infi/2761042
3rd Annual Macrophage-directed Therapies Summit
Format: Seminar and panel discussion
Title: Evaluating the Synergistic Potential of Combination with Other Frontline Treatments to Distinguish the Best Combination Approach
Date and Time: September 30th, 4:00pm ET Registration Link: https://macrophage-directed-therapies.com/take-part/register/
The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc. Doxil® is a registered trademark of Baxter Healthcare Corporation.
What events is Infinity Pharmaceuticals participating in September 2023?
Infinity Pharmaceuticals will participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20 and the 3rd Annual Macrophage-directed Therapies Summit on September 30, 2023.
When is Infinity Pharmaceuticals' presentation at the Oppenheimer Summit?
The presentation by Infinity Pharmaceuticals at the Oppenheimer Summit is scheduled for September 20, 2023, at 1:15 PM ET.
What is the focus of Infinity Pharmaceuticals at the Macrophage-directed Therapies Summit?
At the Macrophage-directed Therapies Summit, Infinity Pharmaceuticals will discuss the synergistic potential of eganelisib with other frontline treatments.
How can I access the presentations from Infinity Pharmaceuticals?
Presentations and archived webcasts from Infinity Pharmaceuticals can be accessed on their website for 30 days after the events.
What is eganelisib developed by Infinity Pharmaceuticals?
Eganelisib is a potentially first-in-class oral immuno-oncology therapeutic that reprograms macrophages to address immune suppression in cancer.
